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1. Introduction 
Leukodystrophies are hereditary disorders of white matter that impair brain that is initially 
normally formed and developed (1, 2). They can affect brain myelin throughout life. The 
disorders are commonly progressive in nature and ultimately fatal. First manifestations are 
often cognitive deterioration and neuropsychological problems. Motor and balance 
difficulties occur, as do visual abnormalities. Classic leukodystrophies lead to a vegetative 
state or death within months to years. In general, the earlier the onset of symptoms, the 
more progressive the disease course.  
Most leukodystrophies are monogenetic disorders. The mutant gene often encodes an 
enzyme or protein that maintains neuronal and/or glial health and is responsible for 
regulation of brain metabolism. Many enzymes involved play a role in lipid metabolism. 
The inability to degrade or synthesize substrate leads to an upstream excess or downstream 
lack of vital lipids. This can cause a wide range of pathology, from inflammatory 
demyelination to axonal degeneration and microglial activation. Hence, the often cited 
prominent demyelination is only one manifestation in leukodystrophies, and myelin-
forming oligodendrocytes are not the only cells affected in these disorders.  
Yet, there are some common characteristics that distinguish the pathology in 
leukodystrophies from that of other disorders. MRI has played a seminal role in 
visualization of the lesion pattern. (3). The demyelinating lesions are usually confluent and 
symmetric. Many of the classic disorders, such as X-linked adrenoleukodystrophy (X-ALD), 
metachromatic leukodystrophy (MLD) and Krabbe, show relative sparing of subcortical 
fibers. Yet again, other disorders have early involvement of the U fibers and other unique 
characteristics, such as cystic rarefaction and degeneration. 
Hereditary disorders that do not show demyelination but rather hypomyelination have 
come to increasing attention (4). Common neurological features in hypomyelinating 
disorders are developmental delay, nystagmus, cerebellar ataxia and spasticity. One of the 
better characterized hypomyelinating disorders is Pelizaeus Merzbacher disease (PMD). 
Beyond this classic disorder, a multitude of other hypomyelinating disorders exist. Only 
about half of the patients with evidence of hypomyelination on MRI come to a definitive 
diagnosis. Yet, specific clinical and MRI features can be pathognomonic and lead to 
diagnosis. 
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The current review aims to present the diagnostic MRI lesion patterns of leukodystrophies, 
as well as the utility of advanced MR techniques. While some of these techniques are 
already established in clinical practice, others are still experimental in nature and require 
future validation.  
2. Conventional brain MRI lesion patterns in LD 
Overall, MR imaging has made an enormous contribution to the field of leukodystrophies 
due to the precise lesion pattern evident on MRI (5). Many leukodystophies classically show 
imaging features that, in some cases, are pathognomonic and, in some cases, highly 
suggestive of the diagnosis. Both demyelinating and hypomyelinating disorders carry 
distinct features and are listed in Tables 1 and 2. While the patterns of maturation of white 
matter are similar on T1 and T2 weighted images, white matter appears to mature at a later 
time on T2 weighted images. This is crucial, as it indicates that T1 weighted imaging may be 
more sensitive to immature myelin than T2 weighted imaging.  
In its most severe form, X-ALD is a lethal neurodegenerative disorder with inflammatory 
demyelination. Defective peroxisomal beta-oxidation causes accumulation of very long-chain 
fatty acids (VLCFA) in tissues and plasma, particularly in the nervous system and adrenal 
glands. At least four clinical phenotypes have been delineated: childhood cerebral (CCALD), 
adult cerebral, adrenomyeloneuropathy (AMN), and female heterozygotes for X-ALD.  
In CCALD, the posterior regions of the brain are involved in 80-90% and the frontal regions 
are involved in 5-10% (6, 7). The lesion evolves in a symmetric confluent fashion starting in 
the splenium or genu of the corpus callosum and spreading into the periventricular white 
matter (Figure 1). The arcuate fibers are most often spared. In the acute phase, a garland of 
contrast enhancement is present. In the final stages, white matter atrophy is seen. The 
systematic progression has given rise to a scoring system of 34 points (8, 9). This pattern is 
markedly different than that seen in the adult form of the disease, AMN, a non-
inflammatory chronic axonopathy.  
In Krabbe disease, the parieto-occipital lesions are also present, although a garland of 
contrast enhancement is never seen (10, 11). MLD shows more diffuse involvement of both 
frontal and posterior regions of the brain (12). Involvement of the corpus callosum is seen 
early, although not as striking as that seen in ALD or GLD. A tigroid pattern is often 
apparent in the centrum semiovale. In contrast to ALD, the outer subarachnoid spaces are 
not enlarged in MLD, even in the most advanced stages of disease.  
Other disorders have characteristic early involvement of the subcortical fibers. Children 
with Canavan disease present with an enlarged head (“megalencephaly”), but show less 
behavioral changes than other leukodystrophies of infancy. (13, 14). Their MRI shows 
diffuse involvement of white matter including the subcortical U fibers (15). There is also 
involvement of basal ganglia and other gray matter structures. Alexander disease is another 
leukodystrophy that often manifests with megalencephaly (16). Imaging studies of the brain 
typically show cerebral white matter abnormalities, preferentially affecting the frontal 
region, although unusual variants are coming to increasing attention (17, 18). 
The MRI of vanishing white matter disease (VWMD) also has a characteristic pattern. It 
shows progressive loss of white matter over time on proton density and FLAIR images 
(19-21). The findings on autopsy confirm the white matter rarefaction and cystic 
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degeneration suggested by the MRI. Regions of relative sparing include the U-fibers, 
corpus callosum, internal capsule, and the anterior commissure. The cerebellar white 
matter and brainstem show variable degrees of involvement but do not undergo cystic 
degeneration. 
 
 
Fig. 1. Lesion Patterns on Conventional MRI in Leukodystrophies and Hypomyelinating 
Disorders 
Brainstem lesion patterns can also often provide critical clues to the diagnosis. 
Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Elevated White 
Matter Lactate (LBSL) has recently been described and shows distinct involvement of the 
pyramidal tracts, medial lemniscus, mesencephalic trigeminal tracts, corticobulbar tracts, 
and superior cerebellar peduncles. (22). Recognition of the distinct lesion pattern led to the 
identification of the responsible gene DARS2, which encodes mitochondrial aspartyl-tRNA 
synthetase.  
In hypomyelinating disorders, the boundaries between gray and white matter often appear 
“blurred” (4). The T2 hypointensity of the white matter is milder in hypomyelination than in 
demyelination and other white matter pathology. Overall, the brain MRI in 
hypomyelination looks like that of a young child, with less well distinguished gray and 
white matter. As opposed to “delayed myelination,” the pattern on brain MRI is unchanged, 
as in myelination is “stuck” on two MRIs 6-12 months apart in a child older than one year of 
age. While at first glance, hypomyelinating disorders may all have a similar MRI 
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appearance, there are a group of disorders for which the MRI scan can provide clues to the 
diagnosis (see Table 2). In these individual disorders attention to the deep gray matter 
structures will often reveal a characteristic “signature” (4).  
 
Leukodystrophy 
Mutated 
genes 
Characteristics on Brain MRI 
Aicardi-Goutières 
syndrome (78, 79) 
TREX1 
Often with microcephaly and intracranial 
calcifications (CT) 
Alexander Disease GFAP 
Macrocephaly with frequent frontal lesion 
predominance in childhood, variants with 
abnormalities in medulla and spinal cord, 
ventricular garlands 
Canavan Disease ASPA 
Macrocephaly, subcortical U fibers  and 
basal ganglia involved 
Cerebral autosomal 
dominant arteriopathy 
with subcortical infarcts 
and leukoencephalopathy 
(CADASIL) 
NOTCH3 
Multiple small hemorrhages. Widened 
perivascular spaces in the centrum 
semiovale and basal ganglia 
Cerebrotendineous 
Xanthomatosis 
CYP27A1 
Cerebellar lesions, calcifications visible on 
CT 
Globoid Leukodystrophy 
(Krabbe Disease) 
GALC 
Posterior predominance, no contrast 
enhancement 
Leukoencephalopathy 
with Brain Stem and 
Spinal Cord Involvement 
and Elevated Lactate 
DARS2 
Characteristic brainstem pattern: pyramidal 
tracts, cerebellar connections and 
intraparenchymal trajectories of trigeminal 
nerve 
Megalencephalic 
Leukodystrophy with 
Cysts (80, 81) 
MLC1, 
GLIALCAM 
Macrocephaly with swelling of cerebral 
white matter and cystic lesions (bilateral 
anterior temporal lobes) 
Metachromatic 
leukodystrophy 
ARSA 
Diffuse with initial subcortical sparing, 
“tigroid pattern” in centrum semiovale 
Vanishing White Matter 
Disease 
EIF2B1-5 
Confluent cystic degeneration, white 
matter signal appears CSF-like 
X-Linked 
Adrenoleukodystrophy 
ABCD1 
CCALD: posterior predominance with 
contrast enhancement in acute phase 
AMN: corticospinal tracts and dorsal 
columns, no contrast enhancement 
Table 1. Characteristics on Brain MRI in Leukodystrophies 
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Hypomyelinating Disorder Mutated genes Characteristics on Brain MRI 
Fucosidosis FUCA1 T2 hypointensity globus pallidus 
GM2 gangliosidoses HEXA, HEXB T2 hyperintensity in the basal ganglia 
Hypomyelination with 
atrophy of the basal 
ganglia and cerebellum 
unknown 
Atrophy of the basal ganglia and 
cerebellum 
Hypomyelination, 
Hypodontia, 
Hypogonadotropic 
Hypogonadism 
unknown 
Early cerebellar atrophy with absence of 
putamen 
Pelizaeus-Merzbacher 
Disease 
PLP1 
Homogeneous T2 hyperintensity of 
cerebral white matter 
Pelizaeus-Merzbacher-
like Disease 
GJC2, 
SLC16A2 
Pontine T2 hyperintensity 
Table 2. Characteristics on Brain MRI in Hypomyelinating Disorders 
Advanced magnetic resonance (MR) imaging techniques, such as proton MR spectroscopic 
and diffusion tensor (DT) MR imaging, permit the investigation of changes in metabolite 
levels and water diffusion parameters in leukodystrophy patients. Both metabolite measures 
and water diffusion parameters offer an opportunity to assess the degree of axonal loss and 
demyelination in the leukodystrophies.  
3. Proton MR spectroscopy 
Magnetic resonance spectroscopy (MRS) offers the unique ability to measure metabolite 
levels in vivo in a non-invasive manner (23, 24, 25). These metabolite quantifications can be 
used to identify disease, measure the severity of an injury, or monitor a patient’s response to 
treatment. Table 3 shows the most well characterized metabolite abnormalities detected by 
MRS in leukodystrophies.  
The resonances seen in the brain by MRS are typically low weight molecules (see Figure 2). 
In the normal brain, the most prominent peak arises from N-acetylaspartate (NAA) at 2.0 
ppm. The other major peaks include creatine (Cr) and phosphocreatine (phospho-Cr), 
which are observed at 3.0 and 3.3 ppm, respectively, as well as choline containing 
compounds. 1H MR spectra acquired with short echo times are characterized by 
additional resonances from myo-inositol (MI) at 3.5 ppm, and glutamate and glutamine, 
which overlap with each other so  that they are often referred to as Glx, at ~2.5 ppm. 
Under normal conditions, the lactate concentration is very low in the adult brain. This 
resonance (observed as a doublet) occurs at 1.32 ppm.  
NAA within the adult brain is found exclusively in neurons, serving as a marker of neuronal 
density and viability and reported to be decreased in a number of neurological disorders.  
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Leukodystrophy or Hypomyelinating 
Disorder 
Systemic metabolites 
Brain metabolites abnormalities on 
proton MR spectroscopy 
Alexander Disease Unknown 
Infantile form: myoinositol 
elevations in white and gray 
matter, decreased N-
acetylaspartate
Canavan Disease 
Urine N-
acetylaspartate
Highly elevated N-
acetylaspartate
Cerebrotendineous 
Xanthomatosis 
Plasma cholestanol Lipid peaks seen in cerebellum 
Globoid Leukodystrophy 
(Krabbe Disease) 
Plasma 
glucocerebrosides, 
psychosine 
Choline and myoinositol 
elevations, 
decreased N-acetylaspartate 
GM2 gangliosidoses GM2 gangliosides 
Infantile: variable choline, 
myoinositol and N-
acetylaspartate. 
Late onset: decreased N-
acetylaspartate 
Hypomyelination with atrophy of 
the basal ganglia and cerebellum 
Unknown 
Increased myoinositol and 
creatine
Leukoencephalopathy with Brain 
Stem and Spinal Cord 
Involvement and Elevated Lactate 
Unknown  
Decreased N-acetylaspartate 
and increased myo-inositol, 
choline and lactate  
Leukoencephalopathy associated 
with a disturbance in the 
metabolism of polyols (83, 84) 
Arabinitol and ribitol 
in urine, plasma and 
CSF
Elevated levels of arabinitol and 
ribitol (coupled resonances 
between 3.5 and 4ppm) 
Megalencephalic 
Leukodystrophy with Cysts 
Unknown 
Decreased ratio of N-
acetylaspartate to Creatine 
Pelizaeus-Merzbacher Disease Unknown 
Variable reports on changes in 
N-acetylaspartate and choline 
Vanishing White Matter Disease
Decreased ratio of 
asialotransferrin to 
transferrin in CSF
Within cystic white matter 
complete absence of all 
metabolites
X-Linked 
Adrenoleukodystrophy 
Plasma very long 
chain fatty acids 
CCALD: Choline elevations 
within normal appearing white 
matter, elevations of lactate 
within the lesion. 
AMN: decreased N-
acetylaspartate in 
adrenomyeloneuropathy  
Table 3. Brain Metabolites Abnormalities on Proton MR Spectroscopy 
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NAA is the source of acetyl in myelin membrane biosynthesis (26) and is coupled to lipid 
metabolism and energy generation (27). Creatine serves as a marker for energy-dependent 
systems in cells and it tends to be low in processes that have low metabolism, such as 
necrosis and infarction. As Cr and phospho-Cr are in equilibrium, the Cr peak is thought to 
remain stable in size, despite bioenergetic abnormalities that occur with multiple 
pathologies. Consequently, the Cr resonance is often used as an internal standard.  
The choline (Cho) resonance arises from signals of several soluble components that resonate 
at 3.2 ppm. This resonance contains contributions primarily from glycerophosphocholine 
(GPC), phosphocholine (PCho), and Cho. Changes in this resonance are commonly seen 
with diseases that have alterations in membrane turnover and in inflammatory and gliotic 
processes (28, 29). The function of MI is not fully understood, although it is believed to be an 
essential requirement for cell growth, an osmolyte, and a storage form for glucose (30). MI is 
primarily located in glia, and an increase in MI is commonly thought to be a marker of 
gliosis (31). Lactate is produced by anaerobic metabolism, and increased lactate has been 
found during hypoxia (32), mitochondrial diseases (33, 34), seizures (35), and in the first 
hours after birth (36, 37).  
In the developing brain, Cho and MI are the dominant peaks in the MR spectrum. Their levels 
are high compared to Cr. In contrast, NAA levels are low in newborns and increase with age, 
while Cho and MI decrease with age. During the first 6 months of life, these metabolic changes 
are most rapid, leveling off at about 30 months of age (50). These changes are crucial, as both 
hypomyelination and delayed myelination affect changes of these metabolites. 
In X-ALD, proton MRS sometimes shows metabolite abnormalities beyond the margins of 
disease depicted by conventional MR imaging (38). The white matter lesion in children with 
X-ALD shows reduced NAA/Cr and increased  Cho/Cr, MI/Cr and Glx/Cr  (30). 
Spectroscopic changes in normal appearing white matter (NAWM) that precede disease 
progression in patients with X-ALD have been described (39). The changes are an increase in 
choline and a decrease in NAA. They occur in areas where subsequent lesion progression is 
observed, but not in the remainder of the brain. These areas may represent a zone of 
impending or beginning demyelination.  
Adrenomyeloneuropathy (AMN) is the adult variant of X-ALD. The disease pathology is 
usually limited to spinal cord and peripheral nerves (“‘pure AMN”) but shows cerebral 
involvement on histopathology. MRS studies showed reduced global NAA/Cho and 
NAA/Cr compared to controls. These changes are most prominent in internal capsule and 
parieto-occipital white matter. Decreased ratios of NAA in the absence of Cho/Cr elevation 
suggest prominent axonal involvement (40). Furthermore, Dubey et al demonstrated that 
the Expanded Disability Status Scale (EDSS) score inversely correlated with global NAA/Cr, 
suggesting a potential role of axonal injury in clinical disability in pure AMN. (40). Brain 
involvement demonstrable by MRI is rare in female subjects heterozygous for X-ALD, 
including those who have clinical evidence of spinal cord involvement. Nevertheless, NAA 
levels are reduced in the corticospinal projection fibers in female subjects with normal 
results on MRI, suggesting axonal dysfunction (41).  
Canavan disease is caused by a deficiency in aspartoacylase (ASPA), an enzyme involved in 
the process of degrading NAA to aspartate and acetate. Deficiency leads to the 
accumulation of NAA, which impairs normal myelination and results in spongiform 
degeneration of the brain (42, 43). The elevations in NAA can be detected by MR 
spectroscopy in vivo (Figure 2), a diagnostic clue that can then be confirmed by urine 
measurement of NAA. The distinctly higher NAA peak can even be detected in the newborn  
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Fig. 2. The spectra of a normal brain are shown at both long echo time (top), TE = 250-280 
ms, and short echo time (bottom), TE = 20-50 ms. The spectra for the disease states are as 
follows: the Canavan spectra are acquired at long echo time, and the ALD and CTX spectra 
are acquired at short echo time.  
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although a radiologist only familiar with MR spectra in adults may not recognize the 
elevation in the newborn as pathologic.  
LBSL is a disorder clinically characterized by slowly progressive signs of pyramidal, 
cerebellar and dorsal column dysfunction. LBSL shows a very distinct MRI pattern, with 
selective involvement of cerebral and cerebellar white matter and brainstem and spinal 
tracks, while U-fibers are spared (44). In LBSL, MR spectroscopy characteristically reveals 
decreased NAA and increased lactate, Cho and MI in the white matter, suggesting axonal 
damage and gliosis (45). Lately, mutations in the DARS2 gene, which encodes mitochondrial 
aspartyl-tRNA synthetase, have been identified as the underlying defect. 
Cerebrotendinous xanthomatosis (CTX) is a rare but treatable disorder characterized by a 
defect in the metabolic pathway of cholesterol (46). Symptoms in infancy include diarrhea, 
cataracts and psychomotor retardation. In adulthood, the spectrum of neurologic 
dysfunction includes mental retardation leading to dementia, psychiatric symptoms, 
premature retinal aging, and epileptic seizures. The most distinctive MR imaging 
abnormalities are bilateral T2 hyperintensities in the dentate nuclei and adjacent 
cerebellar white matter (47). An MRS study showed a reduction in NAA levels and the 
presence of a lactate peak (see Figure 2). NAA decreases are attributed to neuroaxonal 
damage due to neurotoxic deposition of cholesterol (48). A recent case report described 
the presence of abnormal lipid peaks at 0.9 and 1.3 ppm in the cerebellar hemisphere (49). 
These peaks can either be attributed to membrane breakdown or they may serve as 
surrogate markers of major lipid storage, with a potential role in monitoring therapeutic 
response. In addition, one patient had an increase in MI concentration, pointing to gliosis 
and astrocytic proliferation (50). 
The MR spectra of patients with 4H-Syndrome, a rare form of hypomyelinating 
leukodystrophy, reveals low Cho/Cr and NAA/Cr, while a prominent MI peak can be 
observed (51, 52). Low Cho levels are indicative of hypomyelination due to decreased 
membrane synthesis and turnover. In a new syndrome characterized by Hypomyelination 
with Atrophy of the Basal Ganglia and Cerebellum (H-ABC), MI and Cr levels are found to 
be elevated in the cerebral white matter, while NAA and choline levels are normal (53). 
These findings suggest that neither axonal loss nor active demyelination occurs in the 
setting of gliosis. In Pelizaeus Merzbacher disease, another hypomyelinating disorder, there 
have been discrepant reports on metabolite abnormalities detected by MRS. In part, these 
findings may be explained by the concurrent pathophysiologic processes of 
hypomyelination, gliosis, and neuronal loss over time (54).  
4. Diffusion tensor imaging 
While conventional MRI and MR spectroscopy show greatest utility in the diagnoses of 
leukodystrophies, other techniques, such as diffusion tensor imaging, are starting to be 
applied to leukodystrophies as well. Diffusion tensor (DT) MRI measures diffusivity of free 
water molecules in the brain. From the diffusion tensor, one can calculate indices that 
describe features of the orientationally averaged water diffusivity (isotropic part) and the 
water molecule displacements affected by the orientation of a regularly ordered structure in 
the tissue (anisotropic diffusion). Compared to gray matter, in which diffusion shows less 
directional dependence, white matter apparent diffusion is very anisotropic. (55). This 
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property, termed fractional anisotropy (FA), depends on the orientation of the white matter 
tracks and on the degree and integrity of myelination (56-59). 
In X-ALD, DT imaging may reflect the different abnormal white matter (AWM) zones in 
patients with X-ALD (60). We and others have observed that FA decreases and the 
isotropic apparent diffusion coefficient (iADC) increases over the zones toward the center 
of the lesion. The decrease in mean FA indicates the loss of an ordered structure 
governing the directionality of water molecule displacement. The increase in mean iADC 
suggests an increase in free water and a decrease in structures that restrict water 
diffusion. 
In X-ALD, a strong correlation exists between NAA levels and FA, reinforcing the concept 
that both reflect axonal integrity. However, proton MR spectroscopic imaging reveals a low 
NAA level in regions with normal MR and DT imaging findings (61). In contrast, DT 
imaging showed no abnormalities outside the lesion on T2-weighted images. Further, the 
membrane turnover and cell accumulation associated with beginning demyelination, 
recognized in the enhanced choline and creatine signal intensity on proton MR 
spectroscopic imaging, did not have an effect on diffusion parameters. This suggests that 
proton MR spectroscopic imaging may have a higher sensitivity than both conventional MR 
and DT imaging in the early detection of abnormalities related to demyelination or axonal 
loss in X-ALD patients.  
However, in other instances, DTI has proven utility over proton MRSI. In pure AMN 
patients, DTI-based three-dimensional fiber tracking has shown occult tract-specific 
cerebral microstructural abnormalities in patients who had a normal conventional brain 
magnetic resonance image (62). This advance in MR imaging demonstrates that the 
corticospinal tract abnormalities in AMN reflect a centripetal extension of the spinal cord 
long-tract distal axonopathy.  
DTI anisotropy has also proved useful in Krabbe disease (63, 64). In particular, 
measurements of white matter metabolites may help assess disease progression and 
determine optimal candidates for treatment options. Patients with Krabbe disease who 
underwent stem cell transplantation within the 1st month of life showed substantially 
smaller decreases in anisotropy ratios than those who were treated later. These findings 
correlate well with global assessments of disease progression as recognized by 
neurodevelopmental evaluations and conventional MR imaging. 
DT MR imaging studies of cerebral white matter development in human premature and 
term infants demonstrated that, in general, the apparent diffusion coefficient decreases 
while relative anisotropy increases with brain maturation. The most prominent regional 
difference at term is the increased relative anisotropy in the internal capsule, indicative 
of high directionality of diffusion, which could in part be related to myelination. Axonal 
diameter increases before and during myelination. This diameter change could also 
contribute in an important way to the diminished water diffusion perpendicular to the 
orientation of the fiber and thereby contribute to the increase in relative anisotropy. As 
anisotropy precedes myelination changes seen on conventional imaging, it is expected 
that quantitative analysis of diffusion parameters would add to the field of 
hypomyelinating disorders. Yet, little or no data is currently available in this group of 
disorders. Clearly, more systematic research is needed in regards to hypomyelination 
and DTI. 
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5. Recent applications of advanced MR technology 
One major technological advance has been imaging at higher field strength. Magnetic 
resonance imaging at 4 and 7T allows for better visualization of lesion architecture, white 
matter tracts, and gray-white matter distinction compared with 1.5T. The field of proton MR 
spectroscopy has also benefited from higher field strength (65, 66). Better spectral resolution 
results from improved signal-to-noise ratio and chemical-shift dispersion, and this in turn 
leads to more reliable detection of metabolites such as myoinositol and glutamine.   
Using 7T MRSI, decreases in NAA in the cortex of X-ALD patients were detected, which 
appears greater in male hemizygotes than in female heterozygotes and most pronounced 
with the occurrence of white matter lesions in males. (66). Although the cytoarchitecture of 
the cerebral cortex generally appears normal in X-ALD, scattered neuronal loss can be seen 
in gray matter during a pathologic examination. Both ratios of myoinositol and choline to 
creatine were found to be higher in normal appearing white matter of adult ALD patients 
with brain lesions compared to those without lesions. Yet, the interpretation of 7T MRSI 
data also poses challenges. Voxels close to the scalp show poor water and lipid suppression. 
Also, the quantification of spectral data in the presence of substantial radiofrequency 
excitation field (B1) variations is difficult. Therefore, focus has shifted on using adiabatic 
pulses to compensate for radiofrequency inhomogeneity and reduce the chemical shift 
displacement error (67, 68).  
Overcoming some of the shortcomings of DTI, novel methods now exist to map complex 
fiber architectures of white matter and other brain tissues. Diffusion spectrum imaging (DSI) 
allows resolution of regions of 3 way fiber crossings (69-71). On DTI this was not possible as 
fiber crossing led to decreases in FA, making it difficult to distinguish pathological changes 
from normal fiber crossings. The years ahead will likely bring more studies employing DSI 
in leukodystrophy patients.  
Advances have also been in the development of ex vivo MRI and novel magnetic resonance 
contrast agents for imaging of autopsy specimen. In metachromatic leukodystrophy, 
postmortem studies have demonstrated the pathological correlate of the “tigroid stripes” 
characteristically seen on conventional imaging (72). Through direct correlation of 
postmortem MR imaging on 1 cm thick blocks with neuropathology staining, the authors 
were able to show that perivascular clusters of glial cells containing lipid material 
corresponded to the stripes on MRI. 
Using contrast agents ex vivo, the corresponding substrate of imaging can be further 
elucidated. One such example is luxol fast blue that displays a binding affinity for 
myelinated constituents of the brain (73). The specificity of luxol fast blue for lipid 
constituents results in an increase in longitudinal and transverse relaxation rates of tissue 
dependent on myelination status. The relaxation rates of white matter increase sufficiently 
to permit T1-weighted images of ex vivo samples that are similar in contrast behavior to 
T1-weighted in vivo imaging. The contrast increases in MR images of LFB-stained ex vivo 
brain tissues enhancing delineation between upper lamina and the more myelinated 
lower lamina.  
Other advances in MR technology have brought great practical benefits. Sedation and 
anesthesia represent risks in advanced brain disease of LD patients. Using new techniques, 
such as propeller MRI, it has become possible to oversample k space and, thereby, 
compensate for motion and allow follow-up MR imaging without sedation (74, 75). As an 
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alternative to these retrospective motion-correction techniques, it is also possible to 
prospectively correct motion in structural imaging and single-voxel spectroscopy using 
image-based navigators (76-78). In patients with more advanced leukodystrophies, these 
advances may allow for imaging without sedation and thereby give insight into the more 
advanced stages of disease. 
Overall, not one advanced imaging technology is expected to bring about a breakthrough in 
the leukodystrophies. Rather, the multimodal approach with coregistration of high 
resolution imaging with advanced spectroscopic and diffusion imaging will lead to new 
pathophysiological insights in the years to come. Different diseases, varying phenotypes, 
and stages within the disease will require varying imaging modalities. 
6. Conclusions 
MRI has allowed for much progress in the field of leukodystrophies. Prior to arrival of MRI, 
the specific vulnerability of brain white matter was not well understood. Today, MRI has 
helped define disorders through the recognition of specific lesion patterns and their 
evolution over time. This has also led to identification of novel leukodystrophies and the 
genes underlying these disorders. Even in previously well characterized disorders, MRI 
patterns have shed light on disease mechanisms.  
The understanding of the pathology and molecular basis of leukodystrophies has in turn 
allowed for new insight into the significance of MRI changes and elucidated the capabilities 
of MR techniques. Brain MRI today is a valuable tool in monitoring disease progression and 
the success of therapeutic interventions in leukodystrophies. Advances in new techniques 
encourage a multimodal approach employing a variety of sequences sensitive to different 
brain tissue characteristics. Together, these techniques will be able to provide clues to the 
early stages of disease – insight not gained by pathology in the past. 
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